Details of the Drug

General Information of Drug (ID: DMJIBAW)

Drug Name

Budesonide

Synonyms

Bidien; Budenofalk; Budeson; Budesonido; Budesonidum; Budiair; Cortivent; Entocort; Horacort; Inflammide; Micronyl; Miflonide; Preferid; Pulmaxan; Respules; Rhinocort; Spirocort; UDB; Budecort Inhaler; Budesonide Easyhaler; Budesonide MMX; Entocort EC; GionaEasyhaler; Pulmaxan turbohaler; Pulmicort Flexhaler; Pulmicort Nebuamp; Pulmicort Respules; Pulmicort Topinasal; Pulmicort turbuhaler; Rhinocort Aqua; Rhinocort Turbuhaler; Rhinocort alpha; Unit dosebudesonide; B 7777; S 1320; Budesonido [INN-Spanish]; Budesonidum [INN-Latin]; Entocort (TN); Entocort EC (TN); MAP-0010; Noex (TN); Pulmicort (TN); Rhinocort (TN); S-1320; Budesonide (JAN/USAN/INN); Budesonide [USAN:INN:BAN:JAN]; Rhinocort, Pulmicort , Entocort, Symbicort, Noex. Entocort EC, Budesonide; Pregna-1,4-diene-3,20-dione, 16,17-butylidenebis(oxy)-11,21-dihydroxy-, (11beta,16alpha(R))-,and 16alpha,17-((S)-Butylidenebis(oxy))-11beta,21-dihydroxypregna-1,4-diene-3,20-dione; (11-beta,16-alpha)-16,17-(Butylidenebis(oxy))-11,21-dihydroxypregna-1,4-diene-3,20-dione; (11beta,16alpha)-16,17-(Butylidenebis(oxy))-11,21-dihydroxypregna-1,4-diene-3,20-dione; (4aR,4bS,5S,6aS,6bS,8R,9aR,10aS,10bS)-5-hydroxy-6b-(hydroxyacetyl)-4a,6a-dimethyl-8-propyl-4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-2H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-2-one; (4aR,4bS,5S,6aS,6bS,9aR,10aS,10bS)-5-hydroxy-6b-(hydroxyacetyl)-4a,6a-dimethyl-8-propyl-4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-2H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-2-one; (R,S)-11b,16a,17,21,tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with buty raldehyde; (RS)-(11beta,16alpha)-16,17-[Butylidenebis(oxy)]-11,21-dihydroxypregna-1,4-diene-3,20-dione; (RS)-11beta,16alpha,17,21-Tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with butyraldehyde; (S)-16alpha,17-(Butylidenedioxy)-11beta,21-dihydroxypregna-1,4-diene-3,20-dione; 11beta,21-dihydroxy-16alpha,17alpha-(butane-1,1-diyldioxy)pregna-1,4-diene-3,20-dione; 16,17-Butylidenebis(oxy)-11,21-dihydroxypregna-1,4-diene-3,20-dione; 16,17-Butylidenebis(oxy)-11-,21-dihydroxypregna-1,4-diene-3,20-dione; 16-alpha,17-alpha-Butylidenedioxy-11-beta,21-dihydroxy-1,4-pregnadiene-3,20-dione; 16alpha(R),17-(Butylidenebis(oxy))-11beta,21-dihydroxypregna-1,4-diene-3,20-dione; 16alpha-,17alpha-butylidenedioxypregna-1,4-diene-11beta-,21-diol-3,20-dione

Indication

Disease Entry	ICD 11	Status	REF
Asthma	CA23	Approved	[1], [2]

Therapeutic Class

Antiinflammatory Agents

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

430.5

Topological Polar Surface Area (xlogp)

2.5

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [3]
Clearance: The drug present in the plasma can be removed from the body at the rate of 20 mL/min/kg [4]
Elimination: 0% of drug is excreted from urine in the unchanged form [3]
Half-life: The concentration or amount of drug in body reduced by one-half in 2.8 hours [4]
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 0.03964 micromolar/kg/day [5]
Unbound Fraction: The unbound fraction of drug in plasma is 0.13% [4]
Vd: Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 3.9 L/kg [4]
Water Solubility: The ability of drug to dissolve in water is measured as 0.02 mg/mL [3]

Chemical Identifiers

Formula: C25H34O6
IUPAC Name: (1S,2S,4R,8S,9S,11S,12S,13R)-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-propyl-5,7-dioxapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one
Canonical SMILES: CCCC1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@@]5([C@H]4[C@H](C[C@@]3([C@@]2(O1)C(=O)CO)C)O)C
InChI: InChI=1S/C25H34O6/c1-4-5-21-30-20-11-17-16-7-6-14-10-15(27)8-9-23(14,2)22(16)18(28)12-24(17,3)25(20,31-21)19(29)13-26/h8-10,16-18,20-22,26,28H,4-7,11-13H2,1-3H3/t16-,17-,18-,20+,21?,22+,23-,24-,25+/m0/s1
InChIKey: VOVIALXJUBGFJZ-KWVAZRHASA-N

Cross-matching ID

PubChem CID: 5281004
ChEBI ID: CHEBI:3207
CAS Number: 51333-22-3
DrugBank ID: DB01222
TTD ID: D0Y7IU
VARIDT ID: DR00323
INTEDE ID: DR0239
ACDINA ID: D00080

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Glucocorticoid receptor (NR3C1)	TTYRL6O	GCR_HUMAN	Antagonist	[6], [7]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Substrate	[8]
Sulfotransferase 1A1 (SULT1A1)	DEYWLRK	ST1A1_HUMAN	Substrate	[9]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Asthma

ICD Disease Classification

CA23

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Sulfotransferase 1A1 (SULT1A1)	DME	SULT1A1	6.22E-02	1.64E-01	5.58E-01
Cytochrome P450 3A4 (CYP3A4)	DME	CYP3A4	9.85E-01	2.24E-02	7.33E-02

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Budesonide

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Levalbuterol	DM5YBO1	Minor	Increased risk of hypokalemia by the combination of Budesonide and Levalbuterol.	Asthma [CA23]	[35]
Pirbuterol	DMI5678	Minor	Increased risk of hypokalemia by the combination of Budesonide and Pirbuterol.	Asthma [CA23]	[36]
Roflumilast	DMPGHY8	Moderate	Additive immunosuppressive effects by the combination of Budesonide and Roflumilast.	Asthma [CA23]	[37]
-----------

Coadministration of a Drug Treating the Disease Different from Budesonide (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Dronedarone	DMA8FS5	Moderate	Decreased metabolism of Budesonide caused by Dronedarone mediated inhibition of CYP450 enzyme.	Angina pectoris [BA40]	[38]
Posaconazole	DMUL5EW	Major	Decreased metabolism of Budesonide caused by Posaconazole mediated inhibition of CYP450 enzyme.	Aspergillosis [1F20]	[38]
Dalfopristin	DM4LTKV	Moderate	Decreased metabolism of Budesonide caused by Dalfopristin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[38]
Troleandomycin	DMUZNIG	Major	Decreased metabolism of Budesonide caused by Troleandomycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[38]
Pexidartinib	DMS2J0Z	Moderate	Increased metabolism of Budesonide caused by Pexidartinib mediated induction of CYP450 enzyme.	Bone/articular cartilage neoplasm [2F7B]	[39]
Lapatinib	DM3BH1Y	Moderate	Decreased metabolism of Budesonide caused by Lapatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[38]
Tucatinib	DMBESUA	Major	Decreased metabolism of Budesonide caused by Tucatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[38]
Vilanterol	DMF5EK1	Minor	Increased risk of hypokalemia by the combination of Budesonide and Vilanterol.	Chronic obstructive pulmonary disease [CA22]	[35]
Indacaterol	DMQJHR7	Minor	Increased risk of hypokalemia by the combination of Budesonide and Indacaterol.	Chronic obstructive pulmonary disease [CA22]	[36]
Arformoterol	DMYM974	Minor	Increased risk of hypokalemia by the combination of Budesonide and Arformoterol.	Chronic obstructive pulmonary disease [CA22]	[36]
Osilodrostat	DMIJC9X	Moderate	Decreased metabolism of Budesonide caused by Osilodrostat mediated inhibition of CYP450 enzyme.	Cushing syndrome [5A70]	[38]
Ivacaftor	DMZC1HS	Moderate	Decreased metabolism of Budesonide caused by Ivacaftor mediated inhibition of CYP450 enzyme.	Cystic fibrosis [CA25]	[38]
MK-8228	DMOB58Q	Moderate	Decreased metabolism of Budesonide caused by MK-8228 mediated inhibition of CYP450 enzyme.	Cytomegaloviral disease [1D82]	[38]
Stiripentol	DMMSDOY	Moderate	Decreased metabolism of Budesonide caused by Stiripentol mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[38]
Boceprevir	DMBSHMF	Major	Decreased metabolism of Budesonide caused by Boceprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[38]
Telaprevir	DMMRV29	Major	Decreased metabolism of Budesonide caused by Telaprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[38]
Fosamprenavir	DM4W9B3	Major	Decreased metabolism of Budesonide caused by Fosamprenavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[38]
Cobicistat	DM6L4H2	Major	Decreased metabolism of Budesonide caused by Cobicistat mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[38]
Saquinavir	DMG814N	Major	Decreased metabolism of Budesonide caused by Saquinavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[38]
Darunavir	DMN3GCH	Moderate	Decreased metabolism of Budesonide caused by Darunavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[38]
Bempedoic acid	DM1CI9R	Major	Increased risk of tendinitis/tendon rupture by the combination of Budesonide and Bempedoic acid.	Hyper-lipoproteinaemia [5C80]	[40]
Teriflunomide	DMQ2FKJ	Major	Additive immunosuppressive effects by the combination of Budesonide and Teriflunomide.	Hyper-lipoproteinaemia [5C80]	[41]
BMS-201038	DMQTAGO	Moderate	Decreased metabolism of Budesonide caused by BMS-201038 mediated inhibition of CYP450 enzyme.	Hyper-lipoproteinaemia [5C80]	[38]
Berotralstat	DMWA2DZ	Moderate	Decreased metabolism of Budesonide caused by Berotralstat mediated inhibition of CYP450 enzyme.	Innate/adaptive immunodeficiency [4A00]	[38]
Denosumab	DMNI0KO	Moderate	Additive immunosuppressive effects by the combination of Budesonide and Denosumab.	Low bone mass disorder [FB83]	[42]
Crizotinib	DM4F29C	Moderate	Decreased metabolism of Budesonide caused by Crizotinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[38]
Ceritinib	DMB920Z	Major	Decreased metabolism of Budesonide caused by Ceritinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[38]
Selpercatinib	DMZR15V	Moderate	Decreased metabolism of Budesonide caused by Selpercatinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[38]
Idelalisib	DM602WT	Major	Decreased metabolism of Budesonide caused by Idelalisib mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[38]
IPI-145	DMWA24P	Moderate	Decreased metabolism of Budesonide caused by IPI-145 mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[38]
Nivolumab	DMAB9QE	Moderate	Additive immunosuppressive effects by the combination of Budesonide and Nivolumab.	Melanoma [2C30]	[36]
Pembrolizumab	DMFQEA6	Moderate	Additive immunosuppressive effects by the combination of Budesonide and Pembrolizumab.	Melanoma [2C30]	[36]
Ipilimumab	DMJTIYK	Moderate	Additive immunosuppressive effects by the combination of Budesonide and Ipilimumab.	Melanoma [2C30]	[36]
Cemiplimab	DMKMJHE	Moderate	Additive immunosuppressive effects by the combination of Budesonide and Cemiplimab.	Melanoma [2C30]	[36]
Danazol	DML8KTN	Moderate	Decreased metabolism of Budesonide caused by Danazol mediated inhibition of CYP450 enzyme.	Menstrual cycle bleeding disorder [GA20]	[38]
Tecfidera	DM2OVDT	Moderate	Additive immunosuppressive effects by the combination of Budesonide and Tecfidera.	Multiple sclerosis [8A40]	[43]
Siponimod	DM2R86O	Major	Additive immunosuppressive effects by the combination of Budesonide and Siponimod.	Multiple sclerosis [8A40]	[35]
Fingolimod	DM5JVAN	Major	Additive immunosuppressive effects by the combination of Budesonide and Fingolimod.	Multiple sclerosis [8A40]	[44]
Ocrelizumab	DMEZ2KH	Moderate	Additive immunosuppressive effects by the combination of Budesonide and Ocrelizumab.	Multiple sclerosis [8A40]	[45]
Ozanimod	DMT6AM2	Major	Additive immunosuppressive effects by the combination of Budesonide and Ozanimod.	Multiple sclerosis [8A40]	[37]
Fedratinib	DM4ZBK6	Moderate	Decreased metabolism of Budesonide caused by Fedratinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[38]
Nilotinib	DM7HXWT	Moderate	Decreased metabolism of Budesonide caused by Nilotinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[38]
Dasatinib	DMJV2EK	Moderate	Decreased metabolism of Budesonide caused by Dasatinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[38]
Omacetaxine mepesuccinate	DMPU2WX	Moderate	Additive immunosuppressive effects by the combination of Budesonide and Omacetaxine mepesuccinate.	Myeloproliferative neoplasm [2A20]	[46]
Netupitant	DMEKAYI	Moderate	Decreased metabolism of Budesonide caused by Netupitant mediated inhibition of CYP450 enzyme.	Nausea/vomiting [MD90]	[38]
Atezolizumab	DMMF8U0	Moderate	Additive immunosuppressive effects by the combination of Budesonide and Atezolizumab.	Non-small cell lung cancer [2C25]	[36]
Entrectinib	DMMPTLH	Moderate	Decreased metabolism of Budesonide caused by Entrectinib mediated inhibition of CYP450 enzyme.	Non-small cell lung cancer [2C25]	[38]
Rucaparib	DM9PVX8	Moderate	Decreased metabolism of Budesonide caused by Rucaparib mediated inhibition of CYP450 enzyme.	Ovarian cancer [2C73]	[38]
Abametapir	DM2RX0I	Moderate	Decreased metabolism of Budesonide caused by Abametapir mediated inhibition of CYP450 enzyme.	Pediculosis [1G00]	[47]
Lefamulin	DME6G97	Moderate	Decreased metabolism of Budesonide caused by Lefamulin mediated inhibition of CYP450 enzyme.	Pneumonia [CA40]	[48]
Choline salicylate	DM8P137	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Budesonide and Choline salicylate.	Postoperative inflammation [1A00-CA43]	[49]
Lonafarnib	DMGM2Z6	Major	Decreased metabolism of Budesonide caused by Lonafarnib mediated inhibition of CYP450 enzyme.	Premature ageing appearance [LD2B]	[38]
Temsirolimus	DMS104F	Moderate	Increased plasma concentrations of Budesonide and Temsirolimus due to competitive inhibition of the same metabolic pathway.	Renal cell carcinoma [2C90]	[50]
Salsalate	DM13P4C	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Budesonide and Salsalate.	Rheumatoid arthritis [FA20]	[49]
Canakinumab	DM8HLO5	Moderate	Additive immunosuppressive effects by the combination of Budesonide and Canakinumab.	Rheumatoid arthritis [FA20]	[51]
Rilonacept	DMGLUQS	Moderate	Additive immunosuppressive effects by the combination of Budesonide and Rilonacept.	Rheumatoid arthritis [FA20]	[51]
Golimumab	DMHZV7X	Major	Additive immunosuppressive effects by the combination of Budesonide and Golimumab.	Rheumatoid arthritis [FA20]	[52]
Anthrax vaccine	DM9GSWY	Moderate	Antagonize the effect of Budesonide when combined with Anthrax vaccine.	Sepsis [1G40-1G41]	[53]
Voxelotor	DMCS6M5	Moderate	Decreased metabolism of Budesonide caused by Voxelotor mediated inhibition of CYP450 enzyme.	Sickle-cell disorder [3A51]	[38]
Larotrectinib	DM26CQR	Moderate	Decreased metabolism of Budesonide caused by Larotrectinib mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[38]
LEE011	DMMX75K	Moderate	Decreased metabolism of Budesonide caused by LEE011 mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[38]
Pitolisant	DM8RFNJ	Moderate	Increased risk of GI mucosal injury/bleeding risk by the combination of Budesonide and Pitolisant.	Somnolence [MG42]	[37]
Fostamatinib	DM6AUHV	Moderate	Decreased metabolism of Budesonide caused by Fostamatinib mediated inhibition of CYP450 enzyme.	Thrombocytopenia [3B64]	[54]
Brilinta	DMBR01X	Moderate	Decreased metabolism of Budesonide caused by Brilinta mediated inhibition of CYP450 enzyme.	Thrombosis [DB61-GB90]	[38]
Durvalumab	DM4PVDY	Moderate	Additive immunosuppressive effects by the combination of Budesonide and Durvalumab.	Ureteral cancer [2C92]	[36]
-----------


⏷ Show the Full List of 65 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Acetic acid	E00002	176	Acidulant; Buffering agent
Allura red AC dye	E00338	33258	Colorant
Cetyl alcohol	E00061	2682	Coating agent; Emollient; Emulsifying agent; Stiffening agent
D&C red no. 28	E00491	6097185	Colorant
D&C red no. 33	E00261	19116	Colorant
Ethyl acrylate	E00191	8821	Film/membrane-forming agent; Flavoring agent
FD&C blue no. 1	E00263	19700	Colorant
FD&C blue no. 2	E00446	2723854	Colorant
Isopropyl alcohol	E00070	3776	Antimicrobial preservative; Solvent
Quinoline yellow WS	E00309	24671	Colorant
Sodium lauryl sulfate	E00464	3423265	Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Stearic acid	E00079	5281	Emulsifying agent; Solubilizing agent; Viscosity-controlling agent; lubricant
Sunset yellow FCF	E00255	17730	Colorant
Acetyltributyl citrate	E00127	6505	Plasticizing agent
Ammonia	E00007	222	Alkalizing agent
Beta-D-lactose	E00099	6134	Diluent; Dry powder inhaler carrier; Lyophilization aid
Butyl alcohol	E00011	263	Flavoring agent; Solvent
Crospovidone	E00626	Not Available	Disintegrant
Eisenoxyd	E00585	56841934	Colorant
Ferric hydroxide oxide yellow	E00539	23320441	Colorant
Ferrosoferric oxide	E00231	14789	Colorant
Hydroxypropyl cellulose	E00632	Not Available	Binding agent; Coating agent; Emulsifying agent; Film/Membrane-forming agent; Modified-release agent; Suspending agent; Viscosity-controlling agent
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate	E00208	11177	lubricant
Polysorbate 80	E00665	Not Available	Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Potassium hydroxide	E00233	14797	Alkalizing agent
Propylene glycol	E00040	1030	Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Saccharose	E00091	5988	Binding agent; Coating agent; Cryoprotectant; Diluent; Flavoring agent; Suspending agent; Viscosity-controlling agent
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Sodium hydroxide	E00234	14798	Alkalizing agent
Soybean lecithin	E00637	Not Available	Other agent
Talc	E00520	16211421	Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
Triethyl citrate	E00128	6506	Plasticizing agent; Solvent
Water	E00035	962	Solvent
--------------------


⏷ Show the Full List of 35 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Budesonide 3 mg capsule	3 mg	Delayed Release Oral Capsule	Oral
Budesonide 9 mg tablet	9 mg	24 HR Extended Release Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7434).
2	Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
3	BDDCS applied to over 900 drugs
4	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
5	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
6	PXR-mediated induction of human CYP3A4 and mouse Cyp3a11 by the glucocorticoid budesonide. Eur J Pharm Sci. 2009 Mar 2;36(4-5):565-71.
7	Knockouts model the 100 best-selling drugs--will they model the next 100 Nat Rev Drug Discov. 2003 Jan;2(1):38-51.
8	No relevant effect of ursodeoxycholic acid on cytochrome P450 3A metabolism in primary biliary cirrhosis. Hepatology. 2005 Mar;41(3):595-602.
9	Sulfation of budesonide by human cytosolic sulfotransferase, dehydroepiandrosterone-sulfotransferase (DHEA-ST). Drug Metab Dispos. 2002 May;30(5):582-5.
10	Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
11	Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
12	Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
13	Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
14	Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
15	Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
16	Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
17	The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
18	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
19	Progestagenic effects of tibolone are target gene-specific in human endometrial cells. J Soc Gynecol Investig. 2006 Sep;13(6):459-65.
20	Tamoxifen-induced adduct formation and cell stress in human endometrial glands. Drug Metab Dispos. 2010 Jan;38(1):200-7.
21	Proposed role of the sulfotransferase/sulfatase pathway in modulating yolk steroid effects. Integr Comp Biol. 2008 Sep;48(3):419-27.
22	Interindividual variability in acetaminophen sulfation by human fetal liver: implications for pharmacogenetic investigations of drug-induced birth defects. Birth Defects Res A Clin Mol Teratol. 2008 Mar;82(3):155-65.
23	Inhibition of human phenol and estrogen sulfotransferase by certain non-steroidal anti-inflammatory agents. Curr Drug Metab. 2006 Oct;7(7):745-53.
24	Natural products isolated from Mexican medicinal plants: novel inhibitors of sulfotransferases, SULT1A1 and SULT2A1. Phytomedicine. 2001 Nov;8(6):481-8.
25	Kinetic analysis of bile acid sulfation by stably expressed human sulfotransferase 2A1 (SULT2A1). Xenobiotica. 2010 Mar;40(3):184-94.
26	Characterization of human liver thermostable phenol sulfotransferase (SULT1A1) allozymes with 3,3',5-triiodothyronine as the substrate. J Endocrinol. 2001 Dec;171(3):525-32.
27	Crystal structure of human sulfotransferase SULT1A3 in complex with dopamine and 3'-phosphoadenosine 5'-phosphate. Biochem Biophys Res Commun. 2005 Sep 23;335(2):417-23.
28	Sulfation of benzyl alcohol by the human cytosolic sulfotransferases (SULTs): a systematic analysis. J Appl Toxicol. 2016 Sep;36(9):1090-4.
29	Interaction between the glucocorticoid and erythropoietin receptors in human erythroid cells. Exp Hematol. 2009 May;37(5):559-72.
30	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
31	Aldosterone (mineralocorticoid) equivalent to prednisolone (glucocorticoid) in reversing hearing loss in MRL/MpJ-Fas1pr autoimmune mice. Laryngoscope. 2000 Nov;110(11):1902-6.
32	Fluticasone furoate nasal spray in allergic rhinitis. Drugs Today (Barc). 2008 Apr;44(4):251-60.
33	Cytochromes P450 (CYP) in the Poeciliopsis lucida hepatocellular carcinoma cell line (PLHC-1): dose- and time-dependent glucocorticoid potentiation of CYP1A induction without induction of CYP3A. ArchBiochem Biophys. 1996 May 1;329(1):113-22.
34	The glucocorticoid agonist activities of mifepristone (RU486) and progesterone are dependent on glucocorticoid receptor levels but not on EC50 values. Steroids. 2007 Jun;72(6-7):600-8.
35	Cerner Multum, Inc. "Australian Product Information.".
36	Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
37	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
38	Bolland MJ, Bagg W, Thomas MG, Lucas JA, Ticehurst R, Black PN "Cushing's syndrome due to interaction between inhaled corticosteroids and itraconazole." Ann Pharmacother 38 (2004): 46-9. [PMID: 14742792]
39	Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
40	Product Information. Nexletol (bempedoic acid). Esperion Therapeutics, Ann Arbor, MI.
41	Product Information. Arava (leflunomide). Hoechst Marion-Roussel Inc, Kansas City, MO.
42	Product Information. Prolia (denosumab). Amgen USA, Thousand Oaks, CA.
43	Product Information. Vumerity (diroximel fumarate). Alkermes, Inc, Cambridge, MA.
44	Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
45	Product Information. Ocrevus (ocrelizumab). Genentech, South San Francisco, CA.
46	Product Information. Synribo (omacetaxine). Teva Pharmaceuticals USA, North Wales, PA.
47	Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
48	Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
49	Baer PA, Shore A, Ikeman RL "Transient fall in serum salicylate levels following intraarticular injection of steroid in patients with rheumatoid arthritis." Arthritis Rheum 30 (1987): 345-7. [PMID: 3566826]
50	Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
51	Product Information. Arcalyst (rilonacept). Regeneron Pharmaceuticals Inc, Tarrytown, NY.
52	Product Information. Cimzia (certolizumab). UCB Pharma Inc, Smyrna, GA.
53	CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18. [PMID: 20300058]
54	Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.